Company: RPTX
Filing Date: 2025-11-14
Form Type: 8-K
Source: 0001193125-25-283314
Chunk: 1

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-14
Form: 8-K
Item: Item 8.01
Chunk 1
---
Item 8.01 Other Events.

On November 14, 2025, the Company announced that it has entered into a definitive arrangement agreement (the “ Arrangement Agreement”) with XenoTherapeutics, Inc., a Massachusetts non-profitcorporation (“ Parent”) and Xeno Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Parent (together with Parent, “ Xeno”), pursuant to which Xeno will acquire all of the issued and outstanding common shares of the Company (the “ Transaction”). The press release announcing the execution of the Arrangement Agreement is attached hereto as Exhibit 99.1 and is incorporated by reference herein, excluding any information regarding financial results for the three and nine months ended September 30, 2025 or Company business highlights not related to the Transaction. Additional information required to be reported on a Current Report on Form8-Kwith respect to the Transaction will be filed by the Company in a subsequent Current Report on Form8-K.